Updates on Extracorporeal CO2 Removal – May 2014

19 May 2014 Recent News

The latest news and developments related to extracorporeal CO2 removal and the Hemolung RAS. New Case Report: “Low-flow extracorporeal carbon dioxide removal to enable reduced airway pressures in a ventilated patient with a persistent air leak” This user report by Pr. Gilles Capellier and Dr. Loic Barrot describes the use of the Hemolung RAS to enable (read more)

Avoidance Of Intubation For A Lung Transplant Candidate Using Extracorporeal Carbon Dioxide Removal With The Hemolung During An Acute COPD Exacerbation – A Case Report

M. Irlbeck, MD, M. Zoller, MD, T. Weig, MD, Presenting author T. Klaus, MD Department of Anaesthesiology, Hospital of the University of Munich, Munich, Germany This case report describes the use of a novel extracorporeal carbon dioxide removal (ECCO2R) device to facilitate avoidance of intubation in a lung transplant candidate experiencing an acute exacerbation of (read more)

Hemolung RAS chosen as a finalist for the 2014 Medical Design Excellence Awards

9 April 2014 Recent News

We are honored to have the Hemolung RAS recognized as a finalist for the 2014 MDEA Awards. This admission is the result of more than 10 years of dedication and perseverance on the part of our staff, investors, and clinical collaborators who all share a common vision: A better future for patients suffering from acute (read more)

Updates on Extracorporeal CO2 Removal – April 2014

9 April 2014 Recent News

The latest news and developments related to extracorporeal CO2 removal and the Hemolung RAS. New White Paper: “Intubation and Mechanical Ventilation vs. Partial ECCO2R with the Hemolung RAS: Complications and Invasiveness” Intubation and mechanical ventilation are the standard method of support for patients suffering from acute respiratory failure. However, the complications associated with intubation and mechanical (read more)

ALung: Improving the global standard of care for acute respiratory failure

1 April 2014 Recent News

Last year was a banner year for South Side-based ALung Technologies. The local life sciences firm received CE Mark approval and entered select European markets with its Hemolung Respiratory Assist System (RAS), raised a $15.8-million Series B-1 round to support the product launch, and was named the Life Sciences Company of the Year by the Pittsburgh Technology Council's Tech 50 Awards. (read more)

Updates on Extracorporeal CO2 Removal – March 2014

7 March 2014 Recent News

The latest news and developments related to extracorporeal CO2 removal and the Hemolung RAS. “Ultra-protective and independent lung ventilation enabled by minimally invasive extracorporeal carbon dioxide removal: A case report” This report describes a unique case of a difficult-to-ventilate patient with severe drug poisoning resulting in coma and aspiration pneumonia of the right lung. There (read more)

Publication and Conference Opportunities for ECCO2R

4 March 2014 Recent News

With clinical utilization of ECCO2R on the rise, journals and conferences are now focusing on this topic. We encourage all Hemolung users to consider submitting their experiences to conferences and journals for publication. Conference Dates Location Abstract Deadline Link Euro-ELSO 22-24 May 2014 Paris, France 17 March 2014 www.congressecurity.net European Society of Artificial Organs (ESAO) (read more)

New Alternatives for Acute Respiratory Therapy

6 February 2014 Clinical Insights, Recent News

Acute respiratory failure is not uncommon and can occur from a variety of causes to people of all ages. Chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS) are just two of many reasons why a patient may experience respiratory failure and require invasive mechanical ventilation (IMV). Approximately 13.7 million people in the United States are living with COPD, and ARDS averages approximately 160,000 cases per year. While IMV has proven to be an indispensible therapy for persons undergoing such incidents, an increased understanding of further lung injury that can in fact be caused by the ventilator has led to a shift in the paradigms for providing respiratory support. A new device offers a minimally invasive option for respiratory support that may allow patients to either avoid IMV or mitigate its injurious side effects. (read more)

CEO Insights: Changing the standard of care for acute respiratory therapy

31 January 2014 Clinical Insights, Recent News

ALung chairman & CEO Peter DeComo talks about advances in respiratory therapy and his company's Hemolung respiratory system. (read more)

Extracorporeal carbon dioxide removal with the Hemolung RAS to avoid intubation and invasive mechanical ventilation in an acute exacerbation of chronic obstructive pulmonary disease: A case report

16 January 2014 Recent News, User Reports

Hergen Buscher, MD Sydney, Australia This case report describes the use of extracorporeal carbon dioxide removal (ECCO2R) to successfully avoid intubation and mechanical ventilation in an 59-year old man who was experiencing an acute exacerbation of chronic obstructive pulmonary disease (COPD). Invasive mechanical ventilation was considered undesirable due to the potential prognosis of long-term ventilator (read more)